#1B AstraZeneca Year-to-date and Q3 2021 results Conference call and webcast for investors and analysts 12 November 2021#22 Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast. B#33 Speakers Pascal Soriot Executive Director and Chief Executive Officer Dave Fredrickson Executive Vice President, Oncology Business Ruud Dobber Executive Vice President, BioPharmaceuticals Business Marc Dunoyer Chief Executive Officer, Alexion Aradhana Sarin Executive Director and Chief Financial Officer Susan Galbraith Executive Vice President, Oncology R&D Mene Pangalos Executive Vice President, BioPharmaceuticals R&D Leon Wang Executive Vice President, International (for Q&A) 4#4Agenda 4 1 Opening remarks 2 Financial results Oncology 3 4 5 6 BioPharmaceuticals, Emerging Markets Rare Disease Closing remarks and Q&A#51 Opening remarks Pascal Soriot Chief Executive Officer $#6Year to date and Q3 2021: key highlights Positioned for long term sustainable growth Robust growth Commercial execution • Total Revenue $25,406m (+28%) ● $23,187m (+17%) exc. Pandemic COVID-19 vaccine • Core EPS $3.59 (+23%) - $3.62 exc. Pandemic COVID-19 vaccine • 2021 Guidance updated Low twenties percentage total revenue increase excluding COVID-19 vaccine Mid-to-high twenties percentage total revenue increase including Q4 COVID- 19 vaccine sales Growth in Core EPS to $5.05 to $5.40 Broad-based performance Delivering value to patients Oncology $9,744m (+16%) • BioPharmaceuticals ● - CVRM $6,028m (+10%) Respiratory & Immunology $4,456m (+12%) • Rare Disease $1,311m (n/m) Other medicines $1,648 (-16%) • Pandemic COVID-19 vaccine $2,219m (n/m) ● ● Following the science Multiple positive Phase III results Lynparza - prostate cancer Enhertu - breast cancer Imfinzi + tremelimumab - liver cancer Imfinzi - biliary tract cancer PT027-asthma AZD7442-COVID-19 prevention AZD7442-COVID-19 treatment ALXN1840 - Wilson disease Exceptional volume of Phase III read-outs highlights breadth of portfolio 6 Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) September 2021, unless stated otherwise. CVRM = Cardiovascular, Renal and Metabolism; COVID-19 = coronavirus disease 2019; n/m = growth rate not meaningful.#7Year to date and Q3 2021: performance. Oncology, CVRM and Respiratory & Immunology all delivered double digit growth 7 Oncology CVRM Respiratory & Immunology Rare Disease Other medicines Total revenue excl. vaccine Pandemic COVID-19 vaccine Total revenue Growth across disease areas YTD '21 $m 9,744 6,028 4,456 1,311 1,648 23,187 2,219 25,406 growth % Total revenue at actual exchange rates; changes at CER. EM = emerging markets. 16 10 12 n/m (16) 17 n/m 28 Q3 '21 $m 3,383 2,086 1,486 1,311 550 8,816 1,050 9,866 growth % 17 13 25 n/m (28) 32 n/m 48 US EM - EM excl. China - China Growth across geographies (excluding COVID-19 vaccine) Europe Established Rest of World Pandemic COVID-19 vaccine Total revenue YTD '21 $m 8,305 7,479 2,780 4,699 4,442 2,961 2,219 25,406 growth % 29 10 14 12 12 n/m 28 Q3 '21 $m 3,471 2,508 1,018 1,490 1,753 1,084 1,050 9,866 growth % 53 12 30 2 36 20 n/m 48 B#8Late-stage pipeline delivery Important milestones since H1 2021 update Regulatory approvals or other regulatory action Regulatory submission acceptances and/or submissions Major Phase III data readouts or other significant developments Medicine Forxiga roxadustat Saphnelo (anifrolumab) Ultomiris Tagrisso Enhertu AZD7442 Lynparza Imfinzi + tremelimumab Imfinzi Enhertu Fasenra tezepelumab PT027 Ultomiris ALXN1840 AZD7442 Indication (geography) chronic kidney disease (EU, JP) anaemia in CKD: complete response letter (US) systemic lupus erythematosus (US, JP) paroxysmal nocturnal haemoglobinuria, paeds (EU) NSCLC (adjuvant): regulatory submission (JP) breast cancer (2nd-line): RTOR regulatory submission (US) breast cancer (2nd-line): regulatory submission (EU) gastric cancer (2nd-line): regulatory submission (EU) COVID-19 prophylaxis: EUA regulatory submission (US) prostate cancer: phase III primary endpoint met liver cancer: phase III primary endpoint met biliary tract cancer: phase III primary endpoint met HER2+ breast cancer: phase III primary endpoint met breast cancer: breakthrough therapy designation (US) eosinophilic gastritis: orphan drug designation (US) eosinophilic gastroenteritis: orphan drug designation (US) eosinophilic gastritis +/- eosinophilic gastroenteritis: fast track (US) eosinophilic oesophagitis: orphan drug designation (US) asthma: phase III primary endpoints met amyotrophic lateral sclerosis: phase III trial stopped for futility Wilson disease: phase III primary endpoint met COVID-19 (prophylaxis): phase III primary endpoint met COVID-19 (outpatient treatment): phase III primary endpoint met 8 NSCLC = non-small cell lung cancer; RTOR = real time oncology review; EUA = emergency use authorisation; HER2+ = human epidermal growth factor receptor 2 positive; CKD = chronic kidney disease. Status as of 12 November 2021.#92 Financial results Aradhana Sarin Chief Financial Officer www. ******#10Reported profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses ¹ - R&D expenses - SG&A expenses Other operating income Operating profit Tax rate EPS Impact of pandemic vaccine on EPS YTD 2021 $m 25,406 25,043 363 68.8% 17,591 7,152 10,117 1,345 1,348 -24.3% $0.33 ($0.03) change % 28 29 10 (10.7) pp 34 63 21 50 (57) (65) % total revenue 100 99 1 69 28 40 5 LO 5 Q3 2021 $m 9,866 9,741 125 61.4% 7,820 3,610 4,090 37 (1,674) -17.5% ($1.10) $0.01 10 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 1. Includes distribution expenses. R&D = research and development; SG&A= sales, general and administration; pp = percentage points; n/m = growth rate not meaningful. change % 48 47 115 (17.5) pp 78 138 47 (87) (n/m) (n/m) % total revenue 100 99 1 79 37 41 (17) 4#11Core profit and loss Total revenue - product sales - collaboration revenue Gross margin Operating expenses ¹ - R&D expenses - SG&A expenses Other operating income Operating profit Tax rate EPS Impact of pandemic vaccine on EPS YTD 2021 $m 25,406 25,043 363 74.1% 13,649 5,591 7,736 1,346 6,610 16.8% $3.59 ($0.03) change % 28 29 10 (5.8) pp 20 30 14 50 23 23 % total revenue 100 99 1 54 22 30 5 26 Q3 2021 $m 9,866 9,741 125 74.5% 5,138 2,152 2,866 37 2,281 21.6% $1.08 $0.01 11 Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of product sales. 1. Includes distribution expenses. R&D = research and development; SG&A= sales, general and administration; pp = percentage points; n/m = growth rate not meaningful. change % 48 47 115 (4.7) pp 35 46 29 (87) 28 15 % total revenue 100 99 1 52 22 29 I 23 4#12Core operating profit mix and full-year 2021 guidance Continued improvement in the core operating mix Core operating profit mix $m 2,750 2,500 2,250 2,000 1,750 1,500 1,250 1,000 750 500 250 0 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Residual Collaboration Revenue Core Other Operating Income Q2 2021 Q3 2021 Full-year 2021 guidance¹ (CER) Total Revenue Increase by a low-twenties percentage excluding COVID-19 vaccine Increase by a mid-to-high twenties percentage including Q4 COVID-19 vaccine sales Growth to $5.05 to $5.40 Core EPS 1. Prior guidance excluded the revenue and profit impact of sales of the pandemic vaccine. COVID-19 vaccine sales in Q4 2021 are expected to be a blend of the original pandemic agreements and new commercial contracts. The 12 contribution from the vaccine in Q4 2021 is expected to offset investment in R&D and supporting activities for the COVID-19 medicines (the vaccine and AZD7442), resulting in no change to Core EPS guidance. The calculation of Core EPS for guidance is based on 1,418 million weighted average number of shares outstanding during 2021. The number of shares in issue as of the close of the Alexion acquisition was 1,549 million. B#13Net debt and capital allocation priorities Rapid debt reduction a priority post Alexion transaction $bn 12.1 Net debt end 2020 4.5 Net debt Net debt: $24,673m; EBITDA: $7,970m 0.8 Capex Cashflow from Operating Activities 0.0 3.9 Dividends paid Deal payments and receipts¹ 0.2 Other 12.4 Net debt end Sep 2021 (ex-acquisition related) 12.2 Acquisition related² 24.7 Net debt end Sep 2021 Net debt/EBITDA: 3.1x Net debt/EBITDA adjusted for Alexion inventory fair value uplift³: 2.7x ● Capital allocation priorities Strong investment grade credit rating • Reinvestment in the business ● • Value-enhancing business development ● • Progressive dividend policy4 1. Comprises purchase and disposal of intangible assets, payment of contingent consideration from business combinations, purchase and disposal of non-current asset investments, movement in profit participation liability and disposal of investments in associates and joint ventures. 2. Comprises for Alexion acquisition: Upfront payment of $13,349m, payments upon vesting of employee share awards of $203m and movement in net debt related to acquisitions +$1,307m. EBITDA = earnings before interest, tax, depreciation and amortisation; last four quarters. AstraZeneca credit ratings: Moody's: short-term rating P-2, long-term rating A3, outlook negative. S&P Global Ratings: 13 short-term rating A-2, long-term rating A-, CreditWatch neutral. 3. EBITDA adding back the impact of $1,044m (YTD 2020: $nil) unwind of inventory fair value uplift recognised on acquisition of Alexion. 4. Progressive dividend defined as either stable or increasing dividend per share in United States Dollar terms. B#143 Oncology Dave Fredrickson EVP Oncology Business Susan Galbraith EVP Oncology R&D#15Tagrisso and Imfinzi Increased reimbursement continuing to drive demand growth 15 Tagrisso: 13% growth to $3.7bn Approvals/Reimbursements: 64/13 (adjuvant), 91/47 (1L), 91/67 (2L) $m 1,400 1,200 1,000 800 600 400 200 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2019 2020 US Europe EROW EM ● ● ● ● US +13% Cumulative impact of lower diagnosis and testing. Diagnosis < 10% below pre-COVID levels Europe +35% Diagnoses less impacted by the pandemic and offset by new reimbursement EROW +14% Japan +8% EM +1% China -10% 1st-line volume growth after NRDL implementation. Inventory phasing effects $m 700 600 500 400 300 200 100 0 Imfinzi: 17% growth to $1.8bn Approvals/Reimbursements: 74/35 (NSCLC), 63/9 (ES-SCLC) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2019 2020 US Europe EROW EM ● US +3% Diagnosis levels < 10% below pre- COVID baseline Europe +27% Some PACIFIC setting recovery, strong CASPIAN uptake in Germany and France • EROW + 27% CRT rates improving, strong growth in Japan despite mandatory price adjustment in August • EM +77% China benefiting from CASPIAN launch performance EROW= established rest of world; EM = emerging markets; 1L = first line; 2L = second line; ES-SCLC = extensive-stage small cell lung cancer; CRT = chemoradiation therapy; NRDL= national reimbursement drug list. B#16Lynparza The globally leading PARP inhibitor across four tumour types $m 700 600 500 400 300 200 100 0 Q3 Product sales 31% growth to $1.7bn Q4 Q1 2019 US Europe EROW EM Q2 Q3 Q4 2020 Q1 Q2 2021 Q3 Growth in all regions Approvals: 86 (OC), 84 (mBC), 70 (mCRPC) ● US +26% Ovarian and prostate see strong growth, with breast also contributing. OlympiA inclusion in NCCN guidelines benefited Q3 Europe +36% Increasing HRD testing, strong share performance and PROfound launch in Germany EROW +29% Japan +22% - strong PAOLA-1 launch EM +40% China +28% with strong demand growth supported by PAOLA-1 NRDL. Inventory phasing driving quarterly volatility Collaboration revenue¹ $3.1bn recorded, $4.6bn future potential $m 1,000 900 800 700 600 500 400 300 200 100 0 J Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2017 2018 2020 2021 Upfront payment Option payments Regulatory milestones Sales milestones 16 PARP = poly ADP-ribose polymerase; OC = ovarian cancer; mBC = metastatic breast cancer; mCRPC = metastatic castration resistant prostate cancer. 1. at actual exchange rates. Lynparza is being developed and commercialised in collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada. 2019#17Calquence and Enhertu Strong launch trajectories continue 17 $m 400 350 300 250 200 150 100 50 0 Calquence: 146% growth to $843m Approvals/Reimbursements: 70/20 (CLL), 34/13 (MCL) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2019 2020 US Europe EROW EM 2021 • Global $843m; US $752m • US CLL New patient share of 52% in 1st- line BTKI class and 20% overall ¹ ● Global CLL Germany and UK largest growth contributors. Successful launches inc. France and Spain • US MCL Preferred BTKI in relapsed refractory MCL Se M CALQUENCE Watendinte caps 100 mg Am $m 80 60 40 20 0 Enhertu: 134% growth to $147m Approvals/Reimbursements: 9/4 (BC), 4/2 (GC) Q1 Q2 Q3 Q4 2020 US Europe EROW EM Q1 Q2 2021 CLL = chronic lymphocytic leukaemia; MCL = mantle cell lymphoma; BTKI = Bruton tyrosine kinase inhibitor; GC = gastric cancer; 3L = 3rd-line. 1. IQVIA US ALPD Claims data NPS data to Sep-21. Q3 ● ● Total revenue: Global $147m; US $120m Total in-market sales ex-Japan: $293m • US #1 in 3rd-line HER2+ breast cancer, strong launch in 2nd-line gastric cancer Global Strong launch in France continues #1 in all countries launched in 3L HER2+ mBC ENHERTU (am rasturnab denotecan-mok) For Injection 100 mg per vial For en ny P Perry CATORN KEEP REFRIGERATED THE gam Daichi Sankyo AdtraZeneca#18Oncology: R&D pipeline highlights Strong presence at ESMO and WCLC congresses 18 ● ● US FDA BTD received Enhertu DESTINY-Breast03 Superior efficacy versus TDM-1 Unprecedented 2nd-line monotherapy data that rivals 1st-line current standard triplet therapy, with consistency across all sub-groups No new safety concerns identified and no Grade 4 or 5 treatment- related ILD events ESMO Clinical practice guidelines GOOD SCIENCE BETTER MEDICINE BEST PRACTICE Progression-Free Survival pro 100 80 60 40 20 0 1 Censor T-DXd (n = 261) T-DM1 (n=263) 2 3. 4 5 7 8 9 10 11 12 13 14 15 16 17 Time, months 18 19 mPFS, mo (95% CI) 12-mo PFS rate, % (95% CI) HR (95% CI) 20 21 22 23 24 25 26 Patients Still at Risk: T-DXd 251) 261 256 250 244 240 224 214 202 200 183 168 164 150 132 112 105 79 64 T-DM1 (263) 263 252 200 163 155 132 108 96 93 78 65 60 51 43 37 34 29 23 21 16 12 B T-DXd NR (18.5-NE) 75.8 (69.8-80.7) 53 45 36 29 25 19 10 6 4 1 6 1 5 1 Potential new standard of care in 2nd-line HER2+ metastatic breast cancer T-DM1 6.8 (5.6-8.2) 34.1 (27.7-40.5) 0.28 (0.22-0.37) P= 7.8 x 10-22 27 28 29 3 1 1 1 30 311 32 0 0 0 1 0 Lynparza PROpel Innovation in 1st-line prostate cancer • Trial met primary endpoint of a statistically significant improvement in radiographic progression-free survival versus abiraterone alone Clinical benefit irrespective of homologous recombination repair gene mutations Trend in overall survival seen • First trial to show benefit of PARP inhibitor plus a new hormonal agent in for NHA naïve patients in 1st-line setting Potential new standard of care in 1st-line metastatic castrate resistant prostate cancer ESMO = European Society for Medical Oncology; WCLC = World Conference on Lung Cancer; US FDA = United States Food and Drug Administration; BTD = breakthrough therapy designation; NHA = new hormonal agent.#1919 Oncology: R&D pipeline highlights Positive data in liver cancer and biliary tract cancer Imfinzi + treme HIMALAYA 1st-line liver cancer • Combination met primary endpoint of improved overall survival versus sorafenib ● • Positive data for STRIDE (Single Tremelimumab Regular Interval Durvalumab) regimen • Favourable safety profile US FDA ODD received STRIDE = Single Tremelimumab Regular Interval Durvalumab. Imfinzi TOPAZ-1 + chemo in 1st-line biliary tract cancer • Met primary endpoint of improved overall survival versus standard of care chemotherapy • Improvement also seen in progression- free survival and overall response rate Strong safety profile New prospects for immuno-oncology franchise in gastrointestinal cancers US FDA ODD received#20What's next in Oncology Solid pipeline moving forward What's next Selected Phase I/II new medicines adavosertib (WEE1) uterine, ovarian cancer oleclumab (CD73) solid tumours AZD4573 (CDK9) blood cancers AZD5991 (MCL1) blood cancers AZD2936 (PD-1/TIGIT) solid tumours AZD5305 (PARP1) solid tumours New in Phase I✔ ceralasertib (ATR) solid tumours, blood cancers MEDI5752 (PD-1/CTLA4) solid tumours AZD2811 (Aurora B) solid tumours, blood cancers AZD0466 (Bcl-2/xL) solid tumours, blood cancers AZD7789 (PD-1/TIM3) solid tumours New in Phase 1 ✓ What's now Phase III new medicines New Phase III datopotamab deruxtecan multiple cancers monalizumab head & neck cancer New Orpathys Phase III NSCLC Tagrisso NSCLC New Phase III Major Phase III lifecycle management New Lynparza Phase III multiple cancers Imfinzi multiple cancers camizestrant breast cancer 20 WEE1 = tyrosine kinase WEE1; CD73 = ecto-5'-nucleotidase; CDK9 = cyclin-dependent kinase 9 MCL1= induced myeloid leukaemia cell differentiation protein; PD-1 = programmed cell death protein 1; TIGIT = T-cell immunoreceptor with immunoglobulin and ITIM domains; ATR = ataxia telangiectasia and rad3-related kinase; CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; Bcl-2 = B-cell lymphoma 2; TIM3 = T-cell immunoglobulin domain and mucin domain 3. capivasertib breast, prostate cancer tremelimumab multiple cancers Enhertu New Phase III multiple cancers Calquence multiple cancers#214 BioPharmaceuticals, Emerging Markets Ruud Dobber EVP, BioPharmaceuticals Business Mene Pangalos EVP, BioPharmaceuticals R&D 3#22BioPharmaceuticals: Cardiovascular, Renal and Metabolism Total Revenue $6.0bn; growth +10% Farxiga: 51% growth to $2.1bn Strong momentum continues, fastest growing SGLT2i globally 22 $m 900 800 700 600 500 400 300 200 100 0 Q4 2019 Q1 Q2 Q3 2020 US Europe EROW EM Q4 Q1. Q2 2021 Q3 • US +31%, Europe +50% and EMS +74%, boosted by HF and CKD launches • CKD approval in Europe and Japan obtained in the quarter Updated ESC guidelines now recommend Farxiga as 1st-line treatment for HFrEF Forxiga #1 innovative anti-diabetic in China and Brazil US branded K+ binder TRX share¹ Branded leadership extended in the US 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Jul 2019 Sep 2019 Lokelma Nov 2019 SGLT2i = Sodium-glucose transport protein 2 inhibitor; HFrEF = Heart failure with reduced ejection fraction; K+ = potassium; TRx = total prescriptions. 1. IQVIA US monthly total prescription share data Jan 2020 Mar 2020 May 2020 Lokelma Branded competitor Jul 2020 Sep 2020 Nov 2020 Jan 2021 Mar 2021 May 2021 Jul 2021 Volume growth US and Japan, Europe benefitting from new launches Sep 2021 ESC guidelines now recommend novel K+ binders to manage hyperkalaemia 58% B#23BioPharmaceuticals: Respiratory and Immunology Total Revenue $4.5bn; growth +12% ● $m 400 300 200 100 0 Q3 Fasenra 32% growth to $901m Q4 Q1 Q2 Q3 Q4 2019 US Europe EROW EM 2020 Q1 Q2 • US performance driven by NBRx leadership and volume growth 2021 Q3 Leading biologic in eosinophilic asthma¹ Global performance driven by new patient share Fasenra Per 30 mg/ml Breztri COPD launch uptake; sales of $130m Top 8 markets triple FDCs brand share (DOT)² Breztri 4% 12% Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Rapidly increasing market share globally Demand sales volume increase in China following NRDL inclusion ホリエアロスフィ (6) レーストリ 56x DAN $m 1,000 800 600 400 200 0 Q3 Symbicort Resilient performance Q4 Q1 2019 US Europe EROW EM Q2 Q3 Q4 Q1 2020 • Anti inflammatory reliever now approved in 42 countries Symbicort #1 ICS/LABA 23 1. Based on IQVIA MIDAS consolidated total patient top 7 market share (Markets: US, JP, DE, FR, ES, IT, UK) in Q3 2021. 2. IQVIA MIDAS monthly days of therapy month end Aug-21. NBRX = new to brand prescriptions; COPD = chronic obstructive pulmonary disorder; FDCs = fixed dose combinations; ICS = inhaled corticosteroid; LABA = long acting beta agonist. medicine globally Q2 Q3 • Resilient performance especially in US, growth in China 2021 B#24Emerging Markets Total revenue $7.5bn, excluding COVID-19 vaccine revenue Emerging markets +10%¹ China +8%; Ex-China EMs +14%¹ $m 3,500 3,000 2,500 2,000 1,500 1,000 500 0 Q3 Q4 2019 Q1 Q2 Q3 Q4 Q1 2020 China Ex-China EMS COVID-19 vaccine sales Q2 2021 Q3 0 Diversified growth across geographies Addressing global unmet medical need Oncology $2.4bn +4%: Tagrisso $1bn, up 1% due to March 2021 1st-line NRDL inclusion impact in China CVRM $2.9bn, +14%: strong growth for Forxiga ($877m, +74%) as a result of increased demand in China and improved patient access in Latin America. Continued growth for roxadustat in China, approved in South Korea in Q3 Respiratory & Immunology +17%: Pulmicort ($578m, +13%) saw slight COVID-19 impact recovery ahead of VBP implementation in October; Symbicort growth ($457m, +4%) 24 1. Growth number calculated excluding revenue of the COVID-19 vaccine. Growth including the COVID-19 vaccine is as follows: Emerging Market total revenue growth 28%, China +8%; Other EMS +60%. Roxadustat is being commercialised in collaboration with FibroGen Inc. B#25Respiratory & Immunology: R&D pipeline highlights Potential to change standards of care 25 Saphnelo Systemic lupus erythematosus Received US and Japan approval • AHEG scheduled ahead of EU regulatory decision Phase III trial for subcutaneous delivery underway NDC 0310-3040-00 Be only Saphnel Saphnelo™ (anifrolumab-fnia) Injection For Intravenous Infusion After Dilution, Must dilute before use. See prescribing information. Single-dose vial Discard unused portion Store refrigerated at 2°C to 8°C (36°F to 467). Ceep vial in original carton to protect from light. Jo not shake or freeze Rx only 300 mg/2 ml (150 mg/ml) single-dose vial AstraZeneca PT027 Asthma Positive phase III results from both MANDALA and DENALI trials Potentially the first albuterol/ICS combination rescue therapy for the US • Positioned to replace traditional rescue SABA approach with as-needed albuterol/ICS to treat underlying inflammation Regulatory submission anticipated in H1 2022 Tezepelumab Asthma Regulatory submission completed in US, EU and Japan Regulatory decisions expected H1 2022 Orphan Drug Designation in US - eosinophilic oesophagitis Phase III trial in nasal polyps underway AHEG = ad-hoc expert group; ICS = inhaled corticosteroid; SABA = short acting beta agonist. PT027 is being developed in collaboration with Avillion Inc. Tezepelumab is being developed in collaboration with Amgen Inc. US FDA Priority Review received for asthma B#26Vaccines and immune therapies: R&D pipeline highlights Scientific leadership across active and passive immunisation Vaxzevria COVID-19 >1.5bn doses released for global supply by the extended supply chain as of end September ¹ >145m doses have been delivered to COVAX by AstraZeneca and SII to over 125 countries 91% protection against death due to the Delta variant² PRIX GALIEN AZD7442 COVID-19 PROVENT trial (prophylaxis) - 77% reduction of risk of symptomatic COVID-19 TACKLE trial (outpatient treatment) - 50% risk reduction < 7 days from onset 67% risk reduction at < 5 days • US EUA submitted EMA rolling submission underway • Contract discussions ongoing Only long-acting antibody combination to both prevent and treat COVID-19 Nirsevimab Respiratory syncytial virus MELODY trial - 74.5% reduction of medically attended lower respiratory tract infections caused by RSV • MEDLEY trial - similar safety and tolerability profile compared with Synagis • Potential to protect against RSV for an entire season Submissions anticipated in H1 2022 EMA PRIME status granted 1. AstraZeneca supply is 580 million doses. 2. as demonstrated in a RWE study conducted by the University of Edinburgh, source: letter to the Editor, NEJM 20 Oct 21. BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against 26 Death from the Delta Variant. DOI: 10.1056/NEJMC2113864. SII = Serum Institute of India; RWE = real world evidence; RSV = respiratory syncytial virus; EMA = European Medicines Authority; PRIME = priority medicine. Nirsevimab is being developed in collaboration with Sanofi S.A. US FDA BTD received 3#27What's next in BioPharmaceuticals Expanding pipeline What's next Selected Phase I/II new medicines tozorakimab (MEDI3506) (IL33) DKD cotadutide (GLP-1/glucagon) NASH, DKD AZD4831 (MPO) HFpEF AZD5718 (FLAP) CKD, CAD AZD9977 + Farxiga (MCR + SGLT2) HF with CKD zibotentan + Farxiga (ETR + SGLT2) CKD Phase II data ✓ Phase IIb/III start ✓ tozorakimab (MEDI3506) (IL33) asthma, COPD, AD, COVID-19 AZD1402 (IL4Ra) asthma AZD0449, AZD4604 (JAK, inhaled) asthma MEDI7352 (NGF TNF) pain AZD2693 (PNPLA3) NASH AZD8233 (PCSK9) dyslipidaemia Phase II start ✓ Phase llb data ✓ What's now Phase III new medicines AZD7442 COVID-19 nirsevimab respiratory syncytial virus brazikumab inflammatory bowel disease¹ Farxiga multiple indications PT027 asthma IL33 = interleukin-33; DKD = diabetic kidney disease; GLP-1 = glucagon-like peptide-1; NASH = non-alcoholic steatohepatitis; MPO = myeloperoxidase; HFpEF = heart failure with preserved ejection fraction; FLAP = 5-lipoxygenase- 27 activating protein; CAD = coronary artery disease; MCR = mineralocorticoid receptor; ETR = endothelin receptor; AD = atopic dermatitis (eczema); IL4Rα = interleukin-4 receptor alpha; JAK = Janus kinase; NGF = nerve growth factor; TNF = tumour necrosis factor; PNPLA3 = patatin-like phospholipase domain-containing protein 3; PCSK9 = proprotein convertase subtilisin/kexin type 9; SLE = systemic lupus erythematosus 1. trial technically classified as Phase II. tezepelumab severe asthma Major Phase III lifecycle management AZD2816 COVID-19 Saphnelo lupus (SLE) Fasenra multiple indications Breztri/Trixeo asthma#285 Rare Disease Marc Dunoyer Chief Executive Officer, Alexion 100#29Rare Disease Accelerating AstraZeneca's strategic and financial development ● ● Strong financial track record Pre-acquisition: ~$6bn in annual revenues¹ Best-in-class Ultomiris conversion: Achieved >70% in PNH, aHUS on track ● ● Leader in Complement Science Continued C5 inhibition innovation with subcutaneous Ultomiris and ALXN1720 Oral Factor D & subcutaneous anti-properdin in development ● 29 1. FY2020, Alexion financial statements. PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome. Diversified rare disease pipeline 11 molecules in over 20 clinical trials Portfolio of novel platform technologies and medicines Significant growth opportunity: >7,000 rare diseases known to exist, only 5% have FDA approved medicines#3030 Am Building scientific bridges across AstraZeneca and Alexion Immunology & Complement 1000 Protein engineering Patient centricity Al artificial intelligence. MK Gene therapy & Oligonucleotides DevOps excellence A Chemistry & Manufacturing Al & Data analytics S Precision medicine Talent programmes Exploring more opportunities to build two-way bridges and create synergies in R&D#31Rare Disease Q3 2021 Total Revenue $1.3bn 31 $m 900 800 700 600 500 400 300 200 100 0 Rare disease Pro-forma global growth, Q3 2021 +7% li.. +12% +9% US Pro-forma Q3 2020¹ Q3 2021 EU EROW IMDC = Independent Data Monitoring Committee; AL = amyloid light-chain. 1. geographic splits restated. -31% EM Multiple Phase III results across both LCM and NMES • Positive Phase III results for Ultomiris in generalised myasthenia gravis Phase III trial for Ultomiris in amyotrophic lateral sclerosis stopped for futility on IDMC recommendation • Positive Phase III results for ALXN1840 in Wilson disease • Acquired Caelum Biosciences: CAEL-101 Phase III ● development in AL amyloidosis to be accelerated B#3232 Jesse living with gMG Bunny ving with PNH 658 Aira living with HPP Justice living with aHUS 1 Soliris PNH, aHUS, gMG, NMOSD ● ● Rare Disease Q3 2021¹ performance highlights leading C5 franchise ● Global $798m, (-2%) US (+4%), EU (-3%), EM (-40%), EROW (+10%) Strong volume growth in Neurology, offset by successful conversion to Ultomiris and prior year EM tender market order timing • Global $297m, (+31%) ● ● Ultomiris PNH, aHUS ● US (+25%), EU (+77%), EM (n/m), EROW (+5%) Performance driven by strong conversion from Soliris, and 14 new country launches this year Strensiq HPP Global $159m, (+8%) US (+6%), EU (+5%), EM (+75%), EROW (+11%) Strong underlying volume growth in US gMG = generalised myasthenia gravis; NMOSD = neuromyelitis optica spectrum disorder; HPP = hypophosphatasia. 1. Q3 2021 revenues from date of acquisition closing, 21 July 2021 through 30 September 2021; pro-forma growth rates calculated by comparing post-acquisition revenues with the corresponding prior year Q3 revenues adjusted pro-rata to match the post-acquisition period.#33What's next in Rare Disease Advancing diversified pipeline 33 What's next Selected Phase I/II new medicines ALXN1720 (3rd-generation C5) gMG ALXN2040 (Factor D) geographic atrophy ALXN1820 (anti-properdin) haematology ALXN1830 (anti-FcRn) gMG, WAIHA ALXN2050 (Factor D) PNH, gMG, renal indications ALXN1850 (next-generation asfotase alfa) New in hypophosphatasia Phase 1 ✓ What's now Phase III new medicines ALXN1840 Wilson disease acoramidis (ALXN2060) ATTR WAIHA = warm autoimmune haemolytic anaemia; FcRn = neonatal Fc receptor for immunoglobulin G; ATTR= amyloid transthyretin amyloidosis; EVH = extravascular haemolysis. 1. Japan-only trial. Major Phase III lifecycle management Soliris Guillain-Barré syndrome¹ CAEL-101 AL-amyloidosis danicopan (ALXN2040) PNH w/EVH Ultomiris New in Phase III multiple indications#346 Closing remarks and Q&A 100 SETGON#35Pipeline catalysts for 2021 2022 Industry leading news flow 35 |N Regulatory decision Regulatory submission and/or acceptance Key Phase III data readouts Oncology BioPharmaceuticals Rare Disease Q4 2021 AZD7442-COVID-19 prophylaxis (US) - Imfinzi + tremelimumab - NSCLC (1L) (POSEIDON) Lynparza - breast cancer (adjuvant) Lynparza - mCRPC (1L) Enhertu - breast cancer (2L, HER2+) AZD7442-COVID-19 prophylaxis (EU CMA, JP) AZD7442-COVID-19 outpatient treatment (US EUA) Ultomiris - subcutaneous formulation in PNH and aHUS Ultomiris - generalised myasthenia gravis AZD2816-COVID-19 (variants of concern) H1 2022 Brilique - stroke (THALES) (EU, CN) Forxiga - chronic kidney disease (CN) Fasenra - nasal polyps (US) Saphnelo - lupus (SLE) (EU) tezepelumab - asthma (US, EU, JP) Imfinzi +/- tremelimumab - liver cancer (1L) Imfinzi - biliary tract cancer (TOPAZ-1) Enhertu - HER2-low breast cancer (DESTINY-Breast04) Calquence - CLL (ELEVATE-TN) (JP) Koselugo - NF1 (JP, CN) Farxiga - HF (HFpEF) PT027 - asthma (US) Vaxzevria - COVID-19 (US) nirsevimab - respiratory syncytial virus Imfinzi - NSCLC (1L) (PEARL) Imfinzi - cervical cancer (CALLA) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Enhertu - HER2-low breast cancer (DESTINY-Breast04) Farxiga - HFPEF (DELIVER) Ultomiris - neuromyelitis optica spectrum disorder H2 2022 Tagrisso - EGFRm NSCLC (adjuvant) (JP) Enhertu - gastric cancer (2L+, HER2+) (EU) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi - NSCLC (1L) (PEARL) Imfinzi - cervical cancer (CALLA) Imfinzi - locoregional liver cancer (EMERALD-1) Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02) Fasenra- eosinophilic oesophagitis (MESSINA) Ultomiris - neuromyelitis optica spectrum disorder ALXN1840 - Wilson disease acoramidis transthyretin amyloid cardiomyopathy Imfinzi - limited-stage SCLC (ADRIATIC) Imfinzi - liver cancer (locoregional) (EMERALD-1) Enhertu - HER2+ breast cancer (3L) (DESTINY-Breast02) Fasenra - hyper-eosinophilic syndrome (NATRON) Fasenra- eosinophilic oesophagitis (MESSINA) Fasenra - chronic spontaneous urticaria (ARROYO) Fasenra - atopic dermatitis (HILLIER) danicopan - PNH with extravascular haemolysis acoramidis - transthyretin amyloid cardiomyopathy#36Q&A Year-to-date and Q3 2021 Results 36 Pascal Soriot Executive Director and Chief Executive Officer Dave Fredrickson Executive Vice President, Oncology Business Ruud Dobber Executive Vice President, BioPharmaceuticals Business Marc Dunoyer Chief Executive Officer, Alexion Aradhana Sarin Executive Director and Chief Financial Officer Susan Galbraith Executive Vice President, Oncology R&D Mene Pangalos Executive Vice President, BioPharmaceuticals R&D Leon Wang Executive Vice President, International 3#37A Appendix 12#38Investor Relations 38 Chris Sheldon [email protected] Tom Waldron [email protected] Morgan Sanford [email protected] Lauren Swales [email protected] Josie Afolabi [email protected] Christer Gruvris [email protected] Philip Sparks [email protected] Jen Kretzmann [email protected] B#3939 Use of AstraZeneca slides from conference calls and webcasts The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 OAA. Telephone +44 20 3749 5000, www.astrazeneca.com B